On March 8, 2021, the U.S. Centers for Disease Control and Prevention issued new interim recommendations regarding individuals who have been fully vaccinated against COVID-19.
To print this article, all you need is to be registered or login on Mondaq.com.
On Monday, March 8, 2021, the Center for Disease Control
( CDC ) issued new Guidance for Fully Vaccinated People. The CDC
defines fully vaccinated people as those who received
both doses in a 2-dose series, or one dose of a single-dose
vaccine, and two weeks have elapsed since receiving the final dose.
Alongside its recommendations as detailed below, the CDC released a
Background Rationale which provides a
scientific analysis in support of its recommendations.
As set forth in its Guidance, the CDC relaxed its
recommendations on face coverings and social distancing for fully
To print this article, all you need is to be registered or login on Mondaq.com.
On Wednesday, March 10, the House passed the Senate-approved
version of H.R. 1319, the American Rescue Plan Act of
2021, on a 220-211 vote (title-by-title summary available here). No Republicans supported the bill, and
one Democrat, Rep. Jared Golden (D-ME), opposed the bill. Rep. Kurt
Schrader (D-OR), who previously voted against the bill, voted to
support the measure, which aims to accelerate activities to address
the virus and provide additional economic support to individuals,
state and local governments, and small businesses. The bill
provides for a total of $1.88 trillion in federal investments.
On 30 January 2020, the Director-General of the World Health
Organisation (WHO) declared the SARS-CoV-2 outbreak a public
health emergency of international concern
To print this article, all you need is to be registered or login on Mondaq.com.
Sunday, February 28, 2021, was Rare Disease Day. With so much
focus on COVID-19 throughout 2020, it s important to recognize
the continued work done in rare disease drug development by
sponsors and FDA throughout 2020. In addition, a number of policies
implemented in response to COVID-19 are expected to have a positive
impact on rare disease drug development going forward. Yet, the
lasting nature of these policies, post-pandemic, remains uncertain,
creating an opportunity for rare disease drug sponsors to be
proactive in engaging with regulatory authorities and the patient